NCT06980506

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Imaging of Patients With Solid Tumor Cancer Via Intermediate-Size Patient Population Expanded Access Investigational New Drug (IND)

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Monopar Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational imaging agent, MNPR-101-DFO\*-89Zr, with positron emission tomography/computed tomography (PET/CT) imaging, to non-invasively detect the presence of urokinase plasminogen activator receptor (uPAR) binding in solid tumors. uPAR binding is higher in tumors compared to normal tissue in some cancers.

Detailed description

Imaging agent MNPR-101-DFO\*-89Zr will be dosed to adult patients diagnosed with solid tumor cancer followed 3 to 5 days later by PET/CT imaging. The result will determine if there is sufficient uPAR binding, as assessed by the Investigator, to support administration of the companion intervention MNPR-101-PCTA-177Lu in a separate expanded access program (EAP IST-00Cb). The safety of MNPR-101-DFO\*-89Zr will be evaluated as will the amount of radioactivity present in blood samples.

Conditions

• Cancer
• Solid Tumor
• Solid Tumor, Adult

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	MNPR-101-DFO*-89Zr	MNPR-101-DFO\*-89Zr is an antibody radionuclide conjugate intended to image solid tumors expressing uPAR.

Timeline

• First posted: 2025-05-20
• Last updated: 2025-05-22

Locations

1 site across 1 country: United States